ArticleCardiovascular intervention and therapeutics2026
Angiographic residual stenosis and clinical outcomes after elective drug-coated balloon angioplasty for de novo coronary lesions: a single center retrospective study.
Article in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-coated balloon (DCB) Academic Research Consortium (ARC) defined post-procedural percent diameter stenoses (final %DSs) of 40 and 20 as the thresholds of successful DCB angioplasty and drug-eluting stent (DES) placement, respectively. The present single-center, retrospective, lesion-based study clarified the clinically relevant final %DS threshold by including consecutive 297 de novo lesions in 250 patients after successful DCB angioplasty between January 2016 and March 2022, irrespective of vessel size. The whole lesions were stratified into 2 groups of final %DS below 20 (n = 168) and final %DS between 20 and 40 (n = 129). Cumulative 2-year target vessel failure (TVF), comprising of cardiac mortality, non-fatal myocardial infarction, and target vessel revascularization, in final %DS between 20 and 40 group (14.0% with mean observational interval of 629 ± 199 days) was significantly higher than that in final %DS below 20 group (6.5%, 649 ± 168 days, p = 0.033). Final %DS between 20 and 40 was one of the predictors of cumulative 2-year TVF by multiple Cox proportional hazard model (hazard ratio: 2.29, 95% confidence interval: 1.04-5.00, p = 0.039), besides with congestive heart failure and bending lesion. Lesions of calcification, smaller and longer DCB used were the predictors of final %DS between 20 and 40 by multiple logistic regression analysis. Thus, we postulated final %DS of 20 as a candidate of clinically relevant cutoff value of angiographic endpoint associated with favorable outcomes after elective DCB angioplasty for de novo lesions, in response to latest international DCB ARC statement.
Indexed as
Identifiers
42230440What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.